Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications

NCT07094204 is registered in ClinicalTrials.gov with Astellas Pharma Inc as lead sponsor.

NCT NCT07094204
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07094204 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Study of ASP5834 in Participants With Locally Advanced (Unresectable) or Metastatic Solid Tumor Malignancies With KRAS Mutations or KRAS Amplifications
Lead sponsor
Astellas Pharma Inc
Phase
Phase 1
Overall status
Recruiting
Start date
July 25, 2025
Completion date
April 30, 2029
Enrollment
404 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, non-small-cell lung cancer, pancreatic ductal adenocarcinoma, solid tumor